Table 1.
Infrastructure for human vaccine manufacturing in Africa
| Organization | Location | Technology platform | Vaccines | Production scale (doses) |
|---|---|---|---|---|
| Institut Pasteur de Tunis | Tunisia | Bacterial fermentation | BCG | <1 million |
| Institut Pasteur de Dakar | Senegal | Egg-based | Yellow fever (WHO prequalified) | Currently 5 million doses (expansion to 30 million underway) |
| Biovaccines | Nigeria | Not yet operational | Undisclosed | Unknown |
| Innovative Biotech | Nigeria | Insect cell virus-like particles | Preclinical: HIV-1 and Ebola virus | Unknown |
| Vacsera | Egypt | Bacterial fermentation, end to end | DTP, cholera | Undisclosed |
| The Biovac Institute | South Africa | Fill–finish | Variable | ~30 million |
BCG, Bacille Calmette–Guérin; DTP, diphtheria, tetanus toxoid and pertussis; WHO, World Health Organization.